Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | -- |
| Low | -- |
| Bid | -- |
| Offer | -- |
| Previous close | 0.00 |
| Average volume | -- |
|---|---|
| Shares outstanding | 2.61m |
| Free float | 2.55m |
| P/E (TTM) | -- |
| Market cap | 5.22m USD |
| EPS (TTM) | -0.1898 USD |
Data delayed at least 20 minutes, as of Mar 20 2025.
More ▼
Announcements
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
- VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
- VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
- VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
- VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
- Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
- Organovo Provides Business Update
- Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
More ▼
